Drug therapy: Tenofovir

Hepatology

Volumn 52, Issue 2, 2010, Pages 743-747

  Lok, Anna S ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; TENOFOVIR; TENOFOVIR DISOPROXIL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CREATININE CLEARANCE; DRUG ELIMINATION; DRUG MECHANISM; DRUG RESPONSE; FEMALE; HEPATITIS B; HUMAN; NEPHROTOXICITY; PRIORITY JOURNAL; TREATMENT INDICATION;

ADENINE; ANTIVIRAL AGENTS; FEMALE; HEPATITIS B; HUMANS; MIDDLE AGED; PHOSPHONIC ACIDS;

EID: 77955682928     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.23788     Document Type: Article

References (20)

1. Lok AS, McMahon BJ. Practice guidelines: chronic hepatitis B. HEPATOLOGY 2007;45:507-539.
2. Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008;2:263-283.
3. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227-242.
4. Perrillo RP, Lai CL, Liaw YF, Dienstag JL, Schiff ER, Schalm SW, et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. HEPATOLOGY 2002;36:186-194.
5. Wu IC, Lai CL, Han SH, Han KH, Gordon SC, Chao YC, et al. Efficacy of entecavir in chronic hepatitis B patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage. HEPATOLOGY 51:1185-1189.
6. Buster EH, Flink HJ, Cakaloglu Y, Simon K, Trojan J, Tabak F, et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon a-2b. Gastroenterology 2008;135:459-467.
7. Marcellin P, Bonino F, Lau GK, Farci P, Yurdaydin C, Piratvisuth T, et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology 2009;136:2169-2179.
8. Lange CM, Bojunga J, Hofmann WP, Wunder K, Mihm U, Zeuzem S, et al. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. HEPATOLOGY 2009;50:2001-2006.
9. Buster EH, Hansen BE, Lau GK, Piratvisuth T, Zeuzem S, Steyerberg EW, et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology 2009;137:2002-2009.
10. Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. HEPATOLOGY 2009;49:1503-1514.
11. Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral Pregnancy Registry international interim report for July 1, 1989 through July 2009. http://www.apregistry.com/forms/interim-report.pdf. Accessed December 2009.
12. Malik A, Abraham P, Malik N. Acute renal failure and Fanconi syndrome in an AIDS patient on tenofovir treatment - case report and review of literature. J Infect 2005;51:E61-E65. (Pubitemid 40984370)
13. Viread Prescribing Information, http://www.gilead.com/pdf/viread-pi.pdf.
14. Gafni RI, Hazra R, Reynolds JC, Maldarelli F, Tullio AN, DeCarlo E, et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children. Pediatrics 2006;118:e711-e718.
15. Baraclude Package Insert, http://packageinsert.bms.com/pi/pi-baraclude. pdf.
16. Snow-Lampart A, Chappell BJ, Curtis M, Zhu Y, Heathcote EJ, Marcellin P, et al. Resistance surveillance for up to 144 weeks in HBEAG+ and HBEAG- hepatitis B patients treated with tenofovir DF showed no relationship between virologic breakthrough and emergence of genotypic changes in HBV polymerase [Abstract]. HEPATOLOGY 2009;50:532A.
17. Sheldon J, Camino N, Rodes B, Bartholomeusz A, Kuiper M, Tacke F, et al. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther 2005;10:727-734.
18. Amini-Bavil-Olyaee S, Herbers U, Sheldon J, Luedde T, Trautwein C, Tacke F. The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains. HEPATOLOGY 2009;49:1158-1165.
19. Qi X, Xiong S, Yang H, Miller M, Delaney WE 4th,. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Antivir Ther 2007;12:355-362.
20. van Bommel F, de Man RA, Wedemeyer H, Deterding K, Petersen J, Buggisch P, et al. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. HEPATOLOGY 2010;51:73-80.